Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Calliditas Therapeutics (DE:LC8A)
STUTTGART:LC8A
RESEARCH TOOLSreports
Calliditas Therapeutics (LC8A) Stock Price & Analysis
1 Followers
LC8A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€13.90 - €26.00
Previous Close€16.8
Volume0.00
Average Volume (3M)84.00
Market Cap
€470.27M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Beta-0.20
Next Earnings
May 07, 2024EPS Estimate
-€0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume84
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.91Price Target Upside101.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Calliditas Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
LC8A FAQ
What was Calliditas Therapeutics’s price range in the past 12 months?
Calliditas Therapeutics lowest stock price was €13.90 and its highest was €26.00 in the past 12 months.
What is Calliditas Therapeutics’s market cap?
Currently, no data Available
When is Calliditas Therapeutics’s upcoming earnings report date?
Calliditas Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 14 days.
How were Calliditas Therapeutics’s earnings last quarter?
Calliditas Therapeutics released its earnings results on Feb 21, 2024. The company reported -€0.062 earnings per share for the quarter, beating the consensus estimate of -€0.17 by €0.108.
Is Calliditas Therapeutics overvalued?
According to Wall Street analysts Calliditas Therapeutics’s price is currently Undervalued.
Does Calliditas Therapeutics pay dividends?
Calliditas Therapeutics does not currently pay dividends.
What is Calliditas Therapeutics’s EPS estimate?
Calliditas Therapeutics’s EPS estimate is -€0.15.
How many shares outstanding does Calliditas Therapeutics have?
Currently, no data Available
What happened to Calliditas Therapeutics’s price movement after its last earnings report?
Calliditas Therapeutics reported an EPS of -€0.062 in its last earnings report, beating expectations of -€0.17. Following the earnings report the stock price went down -2.618%.
Which hedge fund is a major shareholder of Calliditas Therapeutics?
Currently, no hedge funds are holding shares in DE:LC8A
---
Calliditas Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€33.91 (101.84% Upside)
€33.91 (101.84% Upside)
Blogger Sentiment
Bullish
DE:LC8A Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.36%
12-Months-Change
Fundamentals
Return on Equity
-82.38%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Calliditas Therapeutics
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
---
LC8A Company Deck
---
LC8A Earnings Call
Q4 2024
0:00 / 0:00
---
LC8A Stock 12 Months Forecast
Average Price Target
€33.91
▲(101.84% Upside)
Technical Analysis
Calliditas Therapeutics
―
Akebia Therapeutics
―
Catalyst Pharma
―
FibroGen
―
Esperion
―
Best Analysts Covering LC8A
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+0.07%
reiterated a buy rating 2 months ago
Copying Jon Berggren's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +0.07% per trade.
---